Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484561 · ClinicalTrials.gov registry record · Phase 1
A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT01484561 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 148 participants.
The verdict
NCT01484561, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).
Interventions
- DRUG Placebo
- DRUG CP-690,550 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01484561
The ClinicalTrials.gov registry entry for NCT01484561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01484561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01484561 about?
NCT01484561 is a clinical study titled "A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis". The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).
What is the current status of trial NCT01484561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2012-04. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01484561?
The interventions under investigation include: Placebo (DRUG), CP-690,550 or Placebo (DRUG).
Who is sponsoring clinical trial NCT01484561?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.